In cases with the molecular working diagnosis of MEC, molecular testing was predominantly ordered for confirmation (83%, n = 19/23), and in the confirmatory subset, MAML2 rearrangements were detected in 42% (n = 8/19). Here, MAML2 is linked to mucoepidermoid carcinoma.